Athenex (FRA:2MT0) Total Receivables : €26.31 Mil (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Athenex Total Receivables?

Athenex's Total Receivables for the quarter that ended in Dec. 2022 was €26.31 Mil.

Athenex Total Receivables Historical Data

The historical data trend for Athenex's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Total Receivables Chart

Athenex Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Receivables

Get a 7-Day Free Trial

11.38

15.02

19.40

20.16

26.31

Athenex Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Total Receivables	Get a 7-Day Free Trial															20.16	26.88	32.00	33.24	26.31

Athenex Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Athenex Total Receivables Related Terms

Thank you for viewing the detailed overview of Athenex's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (FRA:2MT0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (FRA:2MT0) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203

Website

https://www.athenex.com

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Athenex (FRA:2MT0) Headlines

No Headlines